BCOR by IHC

Alphabetical Test listing

BCOR by IHC-12376 - Technical only, 12379 - Technical & interpretation

  
BCOR by IHC
  
12376 - Technical only, 12379 - Technical & interpretation
  
LAB12376
LAB12379
  
Bcl-6 transcriptional corepressor
BCoR
IHC
  
Tissue
  

Submit a formalin-fixed, paraffin embedded (FFPE) tissue block

  

FFPE tissue block

  

Tissue section mounted on a charged, unstained slide

  

Ambient (preferred)

  
  • Unlabeled/mislabeled block
  • Insufficient tissue
  • Slides broken beyond repair
  
AHL - Immunohistochemistry
  
Mo - Fr
  
1 - 2 days
  

Immunohistochemical staining and microscopic examination

  

If requested, an interpretive report will be provided

  

Specifications:

Bcl-6 transcriptional corepressor (BCOR or BCoR) encodes a protein which enhances Bcl-6 mediated transcriptional repression and is also involved in epigenetic silencing as a member of the polycomb repressive complex 1 (PRC1) via epigenetic modification of histones. BCOR is necessary for regulation of embryonic stem cell pluripotency and ectodermal and mesodermal development. BCOR immunohistochemistry can be used diagnostically to separate tumors with BCOR gene alteration (rearrangement or internal tandem duplication) other tumors with similar histology.

Staining pattern: Nuclear staining

Applications:

BCOR positivity by immunohistochemistry has been reported in the following:

  • Strong diffuse nuclear staining has been reported in the round cell component of YWHAE-NUTM2 high grade endometrial stromal sarcomas (100% of cases)
  • BCOR positivity has been described in a subset of endometrial stromal sarcomas with ZC3H7B-BCOR or BCOR internal tandem duplications.
  • A minority of low-grade endometrial stromal sarcomas (6%) demonstrate weak positivity in less than 5% of tumor cells.
  • A minority of endometrial stromal nodules (6%) demonstrate weak positivity in less than 5% of tumor cells.
  • A subset of leiomyosarcomas (20%) can demonstrate weak to moderate staining in a subset of tumor cells (<5% to 40% of tumor cells).
  • Clear cell sarcoma of the kidney (100%)
  • Round cell sarcoma (positivity rates vary based on molecular abnormality present)
  • Synovial sarcoma (up to 50% of cases) and rhabdomyosarcomas (7%)
  • Spermatogonia within seminiferous tubules are positive for BCOR.

 

 

Tumors reported to be BCOR negative by immunohistochemistry:

  • Desmoplastic small round cell tumor
  • Myxofibrosarcoma
  • Ossifying fibromyxoid tumor
  • Angiosarcoma
  • Chondrosarcoma
  • Low grade fibromyxoid sarcoma

 

References:

  1. Astolfi A, Fiore M, Melchionda F et al. BCOR involvement in cancer. Epigenetics 2019; 11(7): 835–855.
  2. Chiang S, Lee CH, Steward C et al. BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology. Modern Pathology 2017;1251-1261.
  3. Kao Y, Sung Y, Zhang L et al. BCOR overexpression is a highly sensitive marker in round cell sarcomas with BCOR genetic abnormalities. American Journal Surgical Pathology 2016;40(12):1670-1678.
  
88342 - 1st stain
88341 - each additional stain
  
02/10/2021